Table 5.

Post-study therapies

Post-study therapyPlacebo BID and carbo/paclitaxel (N = 53)Veliparib BID and carbo/paclitaxel (N = 105)
Without any therapy31 (58.5%)46 (43.8%)
With at least one therapy22 (41.5%)59 (56.2%)
Type of medications in post-study therapya
 Docetaxel5 (9.4%)14 (13.3%)
 Erlotinib2 (3.8%)14 (13.3%)
 Gemcitabine4 (7.5%)14 (13.3%)
 Pemetrexed5 (9.4%)21 (20.0%)
 Other12 (22.6%)40 (38.1%)
  • Abbreviation: carbo, carboplatin.

  • aPatients who were on multiple medications in a therapy are counted under each medication.